SEC Form 8-K Summary
Business Context and Reporting Period
Vallon Pharmaceuticals, Inc. filed a Form 8-K dated August 10, 2021, reporting the issuance of a press release containing financial results for the quarter ended June 30, 2021, and a business update. The provided filing identifies Vallon Pharmaceuticals, Inc. as the registrant; it does not identify GRI Bio, Inc.
Financial Results and Liquidity
The filing itself does not provide revenue, net income or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics. These details were included or intended to be included in Exhibit 99.1, but the exhibit text was not provided.
Material Changes Versus Prior Period
The filing does not provide sufficient information to determine material changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing states that the referenced press release included a business update, but it does not reproduce the management commentary, guidance, outlook, risks, contingencies, or unusual items. The information was furnished under Item 2.02 and was not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other SEC filings.
Key Facts to Verify
- Confirm that the filing relates to Vallon Pharmaceuticals, Inc., rather than GRI Bio, Inc.
- Obtain and review Exhibit 99.1 for the quarter ended June 30, 2021 financial results and business update.
- Verify cash, operating cash burn, debt, liquidity, revenue, net loss, and any stated runway.
- Review management’s development, regulatory, financing, and corporate outlook statements.
- Assess any risks or contingencies disclosed in the referenced press release or related filings.